A search for novel therapeutic targets and biomarkers in patients with Systemic Lupus Erythematosus
Withdrawn
- Conditions
- SLEsystemic lupus erythematosus10003816
- Registration Number
- NL-OMON36575
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 75
Inclusion Criteria
Patients full-filling the ACR criteria for systemic lupus erythematosus
Controles: 18 years or older
Exclusion Criteria
Patients: patients with proven other auto-immune disorders, pregnancy and malignancy
Controls: a history or presence of auto-immune disease and current use of immunosupressants or pregnancy
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The expression of IL-7, TSLP, CD30L and their receptors in peripheral blood and<br /><br>urine of patients with SLE as compared to healthy controls. </p><br>
- Secondary Outcome Measures
Name Time Method <p>The longitudinal approach will be used to assess the correlation between the<br /><br>changes in IL-7, TSLP and CD30L and their receptor with the changes in disease<br /><br>activity and immunologic parameters.<br /><br>Identify biomarkers different from healthy controls that reflect disease<br /><br>activity and can be play a role in the pathogenesis of SLE. The results of the<br /><br>proposed studies may contribute to a future treatment strategy by blockade of<br /><br>some of the investigated inflammatory mediators.<br /><br><br /><br>Third objective: Leucocytes will also be stored for DNA isolation, which will<br /><br>be used for analyses of polymorphic sites that might be involved in regulation<br /><br>of transcription of the investigated molecules</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms and therapeutic targets are being investigated in the UMC Utrecht observational study NL-OMON36575 for SLE?
How do novel biomarkers from NL-OMON36575 compare to standard SLE disease activity indices like SLEDAI in clinical utility?
Which cytokine or autoantibody biomarkers in NL-OMON36575 correlate with treatment response in SLE subtypes such as lupus nephritis?
What adverse events are associated with invasive biomarker sampling in SLE patients enrolled in the UMC Utrecht NL-OMON36575 trial?
Are there combination therapies or competitor drugs targeting similar pathways as NL-OMON36575 for SLE treatment development?